21:32 , Jan 20, 2017 |  BC Week In Review  |  Clinical News

PXT864: PLEODIAL-II extension study data

Data from 37 patients with mild AD in the open-label PLEODIAL-II extension of the single-blind, French Phase II PLEODIAL-I trial showed that twice-daily low-, mid- and high-dose oral PXT864 increased mean ADAS-Cog scores from baseline...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Clinical News

Pharnext preclinical data

In rodent models of AD, PXT-864 led to significant alleviation of induced cognitive deficits in the acquisition of long- and short-term memory, novel objects recognition and learning and spatial working memory. PXT-864 also protected neurons...
00:43 , Jul 3, 2014 |  BC Extra  |  Financial News

Synchroneuron secures $20 million in series B

Movement disorder company Synchroneuron Inc. (Waltham, Mass.) secured $20 million in a tranched series B round led by existing investor Morningside Technology Ventures. The company's SNC-102 , a sustained-release formulation of acamprosate, is in Phase...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Clinical News

Acamprosate: Phase II started

Synchroneuron began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate oral SNC-102 once or twice daily for 4 weeks in about 90 patients. Synchroneuron Inc. , Waltham, Mass.   Product: Acamprosate ( SNC-102 )...
07:00 , Jun 25, 2012 |  BioCentury  |  Strategy

Fragile X connection

Last week's deal between Seaside Therapeutics Inc. and Roche has a slew of moving parts, with a different driver for each party. The key for the biotech was granting Roche an option to its lead...
07:00 , Mar 25, 2010 |  BC Innovations  |  Targets & Mechanisms

SK channel activation for alcoholism

Researchers at the Ernest Gallo Clinic and Research Center at University of California, San Francisco have found that activating small conductance calcium-activated potassium channels in the nucleus accumbens region of the brain could help treat...
07:00 , Apr 25, 2005 |  BC Week In Review  |  Clinical News

Acamprosate calcium neurology data

A pooled analysis from five 1-year, double-blind, placebo-controlled trials in 1,681 patients showed that the overall incidence of spontaneously reported adverse events was similar between the 1,998 mg daily Campral arm and the placebo arm....
07:00 , Apr 25, 2005 |  BC Week In Review  |  Clinical News

Acamprosate calcium: Post-marketing study data

A pooled analysis of various studies in 3,395 subjects showed that the incidence of adverse events in patients treated with Campral concomitantly with medications such as antidepressants, anxiolytics, sedatives, hypnotics and analgesics were comparable to...
07:00 , Apr 18, 2005 |  BioCentury  |  Strategy

Reprofiler report card

Reprofiling companies' raison d'être is to get drugs to market faster and cheaper than conventional R&D companies by developing marketed or failed compounds for new applications. Most reprofiled compounds already have been shown to be...
08:00 , Jan 17, 2005 |  BC Week In Review  |  Company News

Forest Laboratories sales and marketing update

FRX launched its Campral acamprosate delayed-released tablets to treat alcohol dependence in patients who are abstinent from alcohol at treatment initiation. Campral is partnered with Merck KGaA (FSE:MRK, Darmstadt, Germany) and received FDA approval in...